Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, represents a valuable laboratory substance extensively utilized in thrombosis investigations. This monoclonal antibody fragment specifically targets the glycoprotein IIb/IIIa binding site on thrombocytes , blocking clot formation . Consequently , it's frequently applied as a tool to examine the processes underlying clotting and to assess the effectiveness of antiplatelet drugs . Distribution is typically limited to academic settings.
```
Abciximab Drug Research: Utilizing C7E3 Antibody and 143653-53-6 in Research Investigations
Ongoing investigation into abciximab, a GPIIb/IIIa, frequently utilizes the monoclonal protein C7E3 and the chemical compound identified as 143653-53-6. These reagents are instrumental for examining abciximab's mode of function, evaluating its therapeutic effect in different patient populations, and understanding potential biomarkers of treatment response. Additional investigation leveraging these specific reagents is expected to generate valuable information for optimizing clinical applications concerning cardiovascular illness.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Investigating Potential Avenues with Abciximab 143653-53-6 via C7E3
Recent work suggest that this antiplatelet agent (identified as 143653-53-6) offers significant research potential, particularly when combined Abciximab bulk with C7E3. Initial findings have that this combination might improve clinical results in several heart-related settings. Further investigation is centered on defining the exact mechanism of action between this inhibitor and C7E3, encompassing study of platelet aggregation and blood vessel protection.
- Current research endeavors aim to refine delivery strategies.
- Animal models are are being employed to further confirm these theories.
- Clinical assessments might be required to thoroughly evaluate therapeutic efficacy.
```
Abciximab (C7E3) for Research: Quality and Details (143653-53-6)
Researchers requiring C7E3 for in vitro investigations should meticulously assess quality and defined parameters . The compound is typically supplied as a freeze-dried powder and comprehensive analytical data including verification by mass spectrometry , binding affinity assays, and bacterial endotoxin testing is available. Verify the manufacturer's CoA specifies required values for related substances and fulfills established quality assurance standards .
Pharmaceutical-Grade Abciximab Details & Stock
Acquiring laboratory-grade Abciximab, specifically referencing the compound C7E3 and identified by the catalog number 143653-53-6, requires detailed consideration of its origin . This antibody is commonly utilized in in vitro studies , particularly those focused on platelet adhesion and occlusion. Existing sources offer this material in varying volumes, typically ranging from g to larger commercial amounts . Kindly recommend reviewing the report of testing to verify purity and applicability for your specific purpose. Furthermore , confirm the stability date before purchasing to maintain ideal effectiveness.
- Common Purity: >95%
- Keeping Conditions: -20°C in controlled conditions
- Intended Purpose: Platelet Aggregation Suppression Studies